MS: New Dosing, A New Withdrawal

Cutting the risk for natalizumab-related PML, update on disability outcomes with ibudilast, and daclizumab pulled from the global market.
Source: Medscape Pharmacists Podcast - Category: Drugs & Pharmacology Authors: Source Type: podcasts